Wednesday, April 08, 2020 1:13:43 PM
Why pay for AYTU Rapid Test? The issue comes down to the clear difference in the (2) Rapid Tests, and this being that AYTU's COVID-19 IgG/IgM is a Serological Test seeking the detection of antibodies in the blood stream. This not only could potentially quickly uncover those who are currently infected, but also those who "were" infected and have already recovered - Serological Testing will prove to be the next frontier in combating and controlling viral outbreaks in the future!
The issue of simple cost-effective rapid testing will be critical, as this combined with field testing will negate the need to visit medical centers or controlled environments, which in turn will also control the spread of the outbreak, which as we know has been infecting medical staff worldwide.
From a recent announcement: "Walgreens announced Tuesday is plans to use Abbott Laboratories' new fast response COVID-19 test to expand drive-through testing for the virus to 15 new sites in seven states, including Illinois." This is only (15) stores, and at best they claim they will test "UP TO" 3,000 people per day at the 15 sites - this is a very small amount. This of course is due to the cost of the "ID Now" Unit, along with the time for each test result.
I've been reading many comments about the Abbott "ID Now" Rapid Test, and although this recently received FDA Approval, there are a couple of critical issues with this Testing Unit that should be addressed. First off, there are specific parameters and guidelines that must be adhered to, to run the test accurately - this of course entails a level of training, which could impact the accuracy of the test results. Secondly, and most importantly is the cost factor, which will greatly impact the speed at which these Test Units are deployed and utilized. I did a little research about the cost factor, and this is what I found: I checked the Abbott Website, but couldn't find any details about product pricing - what I did find is product pricing for the "ID Now" and "Test Kits" on the 'Fisher Scientific' Website. Please see directly below:
https://www.fishersci.com/us/en/catalog/search/products?keyword=ID+NOW+Instrument
23-046-617 Abbott™
NAT024
Abbott ID NOW Instrument
$10,040.00 / Each
The question is: is the above price indicative of the current price, whether it's directly purchased from Abbott, or from a third party - in any event, the price for each Testing Unit is cost prohibitive for massive roll-out, and how quickly can manufacturing be ramped up to meet
the extraordinary current demand?
In addition, the test will require Swab Kits, which are also quite costly - from the Fisher Scientific Website:
https://www.fishersci.com/us/en/catalog/search/products?keyword=ID+NOW+Instrument
23-046-619 Abbott™
425080
Abbott ID NOW Influenza A and B Control Swab Kit
$447.00 / Pack of 20
Again, it's difficult to assess the exact cost for the "ID Now" Testing Unit, along with the Swab Kits, but, if the above pricing is closely indicative of the current cost, then in my opinion this is problematic at best! This is what needs to be weighed when comparing the above to AYTU'S COVID-19 IgG/IgM Rapid Test - I do believe that the issue of speed deployment and accuracy is of the utmost importance at this point, which is exactly why I believe the world requires simplicity at this critical juncture!
The issue of simple cost-effective rapid testing will be critical, as this combined with field testing will negate the need to visit medical centers or controlled environments, which in turn will also control the spread of the outbreak, which as we know has been infecting medical staff worldwide.
From a recent announcement: "Walgreens announced Tuesday is plans to use Abbott Laboratories' new fast response COVID-19 test to expand drive-through testing for the virus to 15 new sites in seven states, including Illinois." This is only (15) stores, and at best they claim they will test "UP TO" 3,000 people per day at the 15 sites - this is a very small amount. This of course is due to the cost of the "ID Now" Unit, along with the time for each test result.
I've been reading many comments about the Abbott "ID Now" Rapid Test, and although this recently received FDA Approval, there are a couple of critical issues with this Testing Unit that should be addressed. First off, there are specific parameters and guidelines that must be adhered to, to run the test accurately - this of course entails a level of training, which could impact the accuracy of the test results. Secondly, and most importantly is the cost factor, which will greatly impact the speed at which these Test Units are deployed and utilized. I did a little research about the cost factor, and this is what I found: I checked the Abbott Website, but couldn't find any details about product pricing - what I did find is product pricing for the "ID Now" and "Test Kits" on the 'Fisher Scientific' Website. Please see directly below:
https://www.fishersci.com/us/en/catalog/search/products?keyword=ID+NOW+Instrument
23-046-617 Abbott™
NAT024
Abbott ID NOW Instrument
$10,040.00 / Each
The question is: is the above price indicative of the current price, whether it's directly purchased from Abbott, or from a third party - in any event, the price for each Testing Unit is cost prohibitive for massive roll-out, and how quickly can manufacturing be ramped up to meet
the extraordinary current demand?
In addition, the test will require Swab Kits, which are also quite costly - from the Fisher Scientific Website:
https://www.fishersci.com/us/en/catalog/search/products?keyword=ID+NOW+Instrument
23-046-619 Abbott™
425080
Abbott ID NOW Influenza A and B Control Swab Kit
$447.00 / Pack of 20
Again, it's difficult to assess the exact cost for the "ID Now" Testing Unit, along with the Swab Kits, but, if the above pricing is closely indicative of the current cost, then in my opinion this is problematic at best! This is what needs to be weighed when comparing the above to AYTU'S COVID-19 IgG/IgM Rapid Test - I do believe that the issue of speed deployment and accuracy is of the utmost importance at this point, which is exactly why I believe the world requires simplicity at this critical juncture!
Recent AYTU News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:08:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/03/2026 09:08:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/03/2026 09:05:35 PM
- Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results • ACCESS Newswire • 02/03/2026 09:05:00 PM
- Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026 • ACCESS Newswire • 01/27/2026 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/20/2026 09:05:29 PM
- Aytu BioPharma Recaps Investor Day Held on January 20, 2026 • ACCESS Newswire • 01/20/2026 09:05:00 PM
- Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA • ACCESS Newswire • 01/20/2026 02:00:00 PM
- Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026 • ACCESS Newswire • 01/13/2026 09:15:00 PM
- Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City • ACCESS Newswire • 01/12/2026 01:00:00 PM
- Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City • ACCESS Newswire • 12/18/2025 02:00:00 PM
- Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults • ACCESS Newswire • 12/15/2025 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/10/2025 09:05:23 PM
- Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference • ACCESS Newswire • 11/24/2025 09:05:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/14/2025 06:26:30 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 09:11:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:08:28 PM
- Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results • ACCESS Newswire • 11/13/2025 09:05:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:35:20 PM
- Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025 • ACCESS Newswire • 11/05/2025 09:05:00 PM
- Aytu BioPharma Announces Patent Term Extension for EXXUA(TM) • ACCESS Newswire • 10/28/2025 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/24/2025 08:03:13 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/24/2025 08:02:41 PM
- Aytu BioPharma to Present at Upcoming October 2025 Conferences • ACCESS Newswire • 10/10/2025 01:00:00 PM
